top of page

ANAVEX New Website - Untitled Page.png

Search

New Alzheimer's Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, and Tolerability

Jan 11, 2016

Alzheimer’s Association International Conference 2016, Toronto, Canada

Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Anastasios Zografidis, Christopher U. Missling

View Poster

Recent Posts

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

bottom of page